Base of tongue squamous cell carcinomas, outcome depending on treatment strategy and p16 status. A population-based study from the Swedish Head and Neck Cancer Register

Authors

  • Anders Högmo Regional Cancer Centre West, Region Västra Götaland, Gothenburg, Sweden
  • Erik Holmberg Regional Cancer Centre West, Region Västra Götaland, Gothenburg, Sweden; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, Sweden
  • Hedda Haugen Cange Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden
  • Johan Reizenstein Department of Oncology, Örebro University Hospital, Örebro, Sweden
  • Johan Wennerberg Otolaryngology/H&N Surgery, Department of Clinical Sciences, Lund University and University Hospital of Scania, Lund, Sweden
  • Martin Beran Department of ENT and Maxillofacial Surgery, NAL Medical Center Hospital, Trollhättan, Sweden
  • Karin Söderkvist Department of Radiation Sciences, Oncology, Umeå University, Umeå and Cancercentre, Umeå University Hospital, Umeå, Sweden
  • Eva Hammerlid Department of Otorhinolaryngology, Head and Neck Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
  • Helena Sjödin Department of Oncology, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden
  • Lovisa Farnebo Department of Otorhinolaryngology – Head and Neck Surgery in Östergötland, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
  • Karl Sandström Otolaryngology, Department of Surgical Sciences, Uppsala University and University Hospital, Uppsala, Sweden
  • Lalle Hammarstedt-Nordenvall Division of Ear, Nose, and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
  • Katarina Zborayova Department of Clinical Sciences, Division of Otorhinolaryngology, Umeå University and University Hospital, Umeå, Sweden
  • Eva Brun Oncology, Department of Clinical Sciences, Lund University and University Hospital of Scania, Lund, Sweden

DOI:

https://doi.org/10.1080/0284186X.2022.2027516

Keywords:

Base of tongue cancer, HPV, survival, radiotherapy, brachytherapy

Abstract

Background

The base of tongue squamous cell carcinoma (BOTSCC) is mainly an HPV-related tumor. Radiotherapy (EBRT) ± concomitant chemotherapy (CT) is the backbone of the curatively intended treatment, with brachytherapy (BT) boost as an option. With four different treatment strategies in Sweden, a retrospective study based on the population-based Swedish Head and Neck Cancer Register (SweHNCR) was initiated.

Material and methods

Data on tumors, treatment and outcomes in patients with BOTSCC treated between 2008 and 2014 were validated through medical records and updated as needed. Data on p16 status were updated or completed with immunohistochemical analysis of archived tumor material. Tumors were reclassified according to the UICC 8th edition.

Results

Treatment was EBRT, EBRT + CT, EBRT + BT or EBRT + CT + BT in 151, 145, 82 and 167 patients respectively (n = 545). A p16 analysis was available in 414 cases; 338 were p16+ and 76 p16−. 5-year overall survival (OS) was 68% (95% CI: 64–72%), with76% and 37% for p16+ patients and p16− patients, respectively. An increase in OS was found with the addition of CT to EBRT for patients with p16+ tumors, stages II–III, but for patients with tumor stage I, p16+ (UICC 8) none of the treatment strategies was superior to EBRT alone.

Conclusion

In the present retrospective population-based study of BOTSCC brachytherapy was found to be of no beneficial value in curatively intended treatment. An increase in survival was found for EBRT + CT compared to EBRT alone in patients with advanced cases, stages II and III (UICC 8), but none of the regimes was significantly superior to EBRT as a single treatment modality for stage I (UICC 8), provided there was p16 positivity in the tumor. In the small group of patients with p16− tumors, a poorer prognosis was found, but the small sample size did not allow any comparisons between different treatment strategies.

Downloads

Download data is not yet available.

Downloads

Published

2022-04-03

How to Cite

Högmo, A., Holmberg, E., Haugen Cange, H., Reizenstein, J., Wennerberg, J., Beran, M., … Brun, E. (2022). Base of tongue squamous cell carcinomas, outcome depending on treatment strategy and p16 status. A population-based study from the Swedish Head and Neck Cancer Register. Acta Oncologica, 61(4), 433–440. https://doi.org/10.1080/0284186X.2022.2027516